Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Investigational New Drugs|December 6, 2006
Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumorsI E L M Kuppens, P O Witteveen, M Schot, et al.
Medical Oncology (Northwood, London, England)|March 23, 2004
The value of abdominal CT scans in decision-making during chemotherapy in ovarian cancerM A L van Lankveld, P H M Peeters, M A van Eijkeren, et al.
Gynecologic Oncology|March 4, 2025
Signal transduction pathway activity in adult-type granulosa cell tumor samplesG J Brink, J W Groeneweg, P van der Ploeg, et al.
Investigational New Drugs|May 1, 2009
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumorsR L Oostendorp, P O Witteveen, B Schwartz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2010
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumorsD S Boss, P O Witteveen, J van der Sar, et al.
Cancer Chemotherapy and Pharmacology|September 27, 2012
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairmentL A Devriese, P O Witteveen, S Marchetti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 24, 1999
Assessment of the quality of life of patients with advanced and end-stage cancer or serious infections with a symptom-based or an impact-based instrumentP O Witteveen, H M Jacobs, M A van Groenestijn, et al.
Seminars in Oncology|November 5, 1997
Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysisJ P Neijt, S A Engelholm, P O Witteveen, et al.
The Netherlands Journal of Medicine|December 31, 2020
Intraperitoneal treatment for advanced ovarian cancer, the Dutch experience. What did we learn?M J A Rietveld, J van der Velden, A M Westermann, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 14, 2009
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumorsR L Oostendorp, J Loftiss, S Goel, et al.
Pageof 4